AI Biology & Protein Design Fundraising: Isomorphic, Xaira

How Isomorphic Labs, Xaira, Chai Discovery, Evolutionary Scale (ESM3), Enveda, Iambic, Terray, Cradle, Latent Labs, Basecamp Research.

Raising Capital for AI Biology Foundation Models, Digital Cell & Protein Design Startups

AI biology foundation models, digital cell, generative protein, small-molecule design is the fastest-growing biotech-adjacent category — Isomorphic Labs $600M Apr-2025 Thrive Capital-GV-Alphabet (first external round, $600M+ Novartis, Lilly deals $1.7B+ potential milestones), Xaira Therapeutics $1B seed Apr-2024 ARCH Venture Partners-Foresite-F-Prime-NEA-Sequoia-Lightspeed (David Baker RFdiffusion, Marc Tessier-Lavigne, Hetu Kamisetty), Evolutionary Scale (ESM3 Jun-2024, $142M seed Nat Friedman-Daniel Gross-Amazon-Nvidia-Lux, Alex Rives ex-Meta FAIR), Chai Discovery ($30M seed Sep-2024 Thrive-OpenAI-Dimension, Chai-1 open, Chai-2 all-atom Nov-2024 outperforms AlphaFold 3 on antibody-antigen), Iambic Therapeutics ($100M A Aug-2024 Nvidia-Ascenta-Catalio, Enchant, Neural PLEX), Enveda Biosciences ($55M C Oct-2024 Kinnevik-Nvidia, natural-product LLM, PRISM), Terray Therapeutics ($120M B May-2024 Bracket-Two Bear-Nvidia, tera, ML fine-tune $1T+ measurements), Recursion Pharmaceuticals $RXRX (merged Exscientia Nov-2024 $712M all-stock, $250M Nvidia Jul-2023, LOWE, Boltz-1 open May-2024), Cradle Bio ($73M B Jun-2024 IVP-Index-Kindred, $24M A Nov-2023, protein-engineering generative model), Latent Labs ($50M seed Feb-2025 Radical Ventures-Sofinnova-Google Ventures, ex-DeepMind AlphaFold team), Basecamp Research ($60M B Sep-2024 Singular-S32-Coefficient, BaseGraph 9.8B protein sequences, BaseFold), Ginkgo Bioworks $DNA (foundry, AI, Google Cloud $1.1B partnership Aug-2024), Genesis Therapeutics ($200M B Aug-2023 Andreessen-Nvidia-Menlo, GEMS platform, Eli Lilly deal), Insilico Medicine ($95M E Mar-2024 Value Partners-Prosperity7, Pharma.AI, INS018_055 Phase 2 anti-fibrotic), Absci $ABS (generative-antibody, AstraZeneca-Almirall, Merck deals), Generate:Biomedicines ($273M C Sep-2023 Nvidia-Amgen-Abu Dhabi, Chroma protein-diffusion, Novartis-Amgen deals), EvolutionaryScale ESM3 (98B parameter, Amazon-Nvidia backed), plus Google DeepMind Isomorphic Labs (AlphaFold 3 May-2024 Nature paper with Isomorphic, all-atom, ligand, nucleic-acid), OpenAI Life Sciences (Retro Biosciences $180M partnership 2023), Anthropic Claude Bio-adj, Meta FAIR ESM Metagenomic Atlas $9B+ proteins, Baker Lab RoseTTAFold, RFdiffusion open-source, Baker Lab All Atom Diffusion May-2024, plus infrastructure, platform — Nvidia BioNeMo, Clara (Nvidia partner tier for Recursion, Terray, Iambic, Genesis, Insilico, Cadence Molecular, Schrödinger $SDGX, BenevolentAI), OpenFold, AlphaFold-Multimer, Boltz-1 (MIT-Recursion-Genentech-JAX open May-2024), Boltz-2 Nov-2024, Chai-2 all-atom, ESM3, RFdiffusion All Atom, plus adjacent — Manas AI (Reid Hoffman-Siddhartha Mukherjee, Jan-2025 launch $24.6M General Catalyst-Greylock), 310.ai ($30M seed 2024 co-Ranomics-Menten-adj), Endless Health-adj, Nabla Bio ($26M A Feb-2024 Radical-Menlo, generative antibody), Cyrus Biotechnology (Rosetta-legacy), Menten AI, Meloria Bio, Adaptyv Bio (protein-testing loop), Enzymit, Innophore, Protai, PostEra ($24M B 2022, Moderna partnership), plus tools, wet-lab, closed-loop — Emerald Cloud Lab-Strateos-Culture Biosciences-Arctoris-Ganymede-Benchling-LatchBio-Colossal Biosciences infrastructure stack.

Why 2026 is different

Four unlocks: (1) AlphaFold 3 (DeepMind-Isomorphic May-2024 Nature), ESM3 98B (Evolutionary Scale Jun-2024), Chai-2 all-atom (Chai Discovery Nov-2024), Boltz-2 (MIT-Recursion-Genentech-JAX Nov-2024), RFdiffusion All Atom (Baker Lab), Isomorphic AlphaFold 3 finally cracked all-atom, ligand, nucleic-acid, antibody-antigen prediction at sub-2Å RMSD accuracy that pharma-BD, wet-lab-validation-team, IND-package-team, clinical-development-team can operationalize for real programs, unlocking Novartis, Lilly, Roche, BMS, Merck, AstraZeneca, GSK, Amgen, Sanofi, Pfizer, Takeda, Boehringer, Bayer, Novo Nordisk BD, partnership, milestone-royalty deal-flow at $500M-$3B+ per program-slate. (2) Xaira Therapeutics $1B seed Apr-2024 (ARCH-Foresite-F-Prime-NEA-Sequoia-Lightspeed, largest bio-seed ever, David Baker RFdiffusion, Marc Tessier-Lavigne, Hetu Kamisetty), Isomorphic Labs $600M Apr-2025 (first external round, Thrive-GV-Alphabet, $1.7B Novartis-Lilly deals Jan-2024), Recursion-Exscientia $712M merger Nov-2024, Generate:Biomedicines $273M C Sep-2023 ($2.4B valuation), Insilico $95M E Mar-2024 ($1B+ valuation) validated AI-biology-foundation-model as a top-tier venture category and gave every downstream operator a comparable at $1-3B private-round valuations. (3) Nvidia BioNeMo, Clara Discovery, Nvidia DGX Cloud, Nvidia Preferred Partner tier (Recursion $250M Jul-2023, Genesis, Iambic, Enveda, Terray, Absci, Insilico, Cadence Molecular, Schrödinger, BenevolentAI), AWS, Google Cloud, Azure, CoreWeave, Nebius, Lambda, Together AI, Crusoe, Ginkgo-Google $1.1B Aug-2024 partnership commoditized H100, H200, B200, GB200, Blackwell Ultra compute, BioNeMo, foundation-model stack, wet-lab-integration, closed-loop for every bio-startup, shrinking the cost, timeline of a Nature-tier model, IND-track pipeline from $500M-$2B to $50-300M. (4) FDA Good Machine Learning Practice (FDA, Health Canada, MHRA Oct-2021, Jan-2024 update), White House EO 14110, NIST AI RMF, EU AI Act biotech generative-AI Art. 50, Annex III, AI Bio-Risk Report (RAND, Anthropic, OpenAI, DeepMind 2024), Bletchley, Seoul, Paris AI Safety Summit biosecurity commitments, BIS export-controls on frontier-bio-AI Jan-2025 gave AI-biology, generative-protein, digital-cell startups a workable regulatory, biosecurity, export-control framework that pharma-BD, IRB, biosafety-committee, regulatory-team can operationalize.

Realistic capital stack

Seed $10-50M for founding-team, first published-benchmark, wet-lab, Nvidia BioNeMo, BioNeMo/AWS/Google/Azure integration, 1-2 pharma design-partner (Chai Discovery $30M seed Sep-2024 Thrive-OpenAI-Dimension, Evolutionary Scale $142M seed Jun-2024 Nat Friedman-Daniel Gross-Amazon-Nvidia-Lux, Latent Labs $50M seed Feb-2025 Radical-Sofinnova-GV, Manas AI $24.6M General Catalyst-Greylock Jan-2025, Nabla Bio $26M A Feb-2024 Radical-Menlo, Adaptyv Bio, Basecamp Research pre-B, plus the outlier — Xaira Therapeutics $1B seed Apr-2024 ARCH-Foresite-F-Prime-NEA-Sequoia-Lightspeed for star-team, Baker Lab, Tessier-Lavigne, wet-lab-integration, Sanofi-anchor). Series A $50-200M for 5-15 owned-programs, 3-8 pharma-partnership BD, $100M+ deal-value, wet-lab-throughput, IND-track-first-asset (Iambic $100M A Aug-2024 Nvidia-Ascenta-Catalio $700M+ valuation, Cradle $73M B Jun-2024 IVP-Index-Kindred, Genesis $200M B Aug-2023 a16z-Nvidia-Menlo, Enveda $55M C Oct-2024 Kinnevik-Nvidia). Series B/C $100-400M for 15-50 owned-programs, 8-20 pharma-partnership BD, $500M-$2B deal-value, IND-cleared assets, Phase 1/2 readouts (Terray $120M B May-2024 Bracket-Two Bear-Nvidia, Generate:Biomedicines $273M C Sep-2023 Nvidia-Amgen-Abu Dhabi $2.4B valuation, Insilico $95M E Mar-2024 Value Partners-Prosperity7 $1B+, Basecamp $60M B Sep-2024 Singular-S32-Coefficient). Growth, IPO-track, M&A $300M-$1B+ for 30-100+ programs, 20+ pharma partnerships, $2B+ cumulative deal-value, Phase 2/3 assets (Xaira $1B seed Apr-2024, follow-on-track, Isomorphic $600M Apr-2025 Thrive-GV-Alphabet, $1.7B Novartis-Lilly deals, Recursion-Exscientia $712M merger Nov-2024, $250M Nvidia Jul-2023, Ginkgo $1.1B Google Aug-2024 partnership, $DNA public, Schrödinger $SDGX, Absci $ABS, Recursion $RXRX public-comps). Non-dilutive, government: US NIH ARPA-H ($2.5B+ 2025 budget, BRIDGE2AI $130M+), NSF AI Institutes, DOE Genomic Science, HPC allocation, DARPA BTO, Insight, Bio-MOD, BARDA biosecurity, DOD DARPA, JASON, UK Wellcome Trust, BBSRC, UKRI, AI Growth Zones, AI Opportunities Jan-2025, EU EIT Health, EIC Accelerator, Horizon Europe, EU AI Factories €10B, EMBL-EBI, Japan AMED, METI, RIKEN, Fugaku, PFN, Korea KISTI, KAIST-KRIBB, Singapore A*STAR, BII-BTI, EDBI, Temasek Life Sciences, UAE MBZUAI, G42 M42, Mubadala Health, plus AWS, Google Cloud, Azure, Nvidia, CoreWeave, Nebius, Lambda, Together AI, Crusoe partner, credit programs ($100k-$5M+ compute-credit per startup).

Common failure modes

Building an AI-biology foundation-model without a proprietary wet-lab, closed-loop, data-generating advantage — post-AlphaFold 3, ESM3, Chai-2, Boltz-2, RFdiffusion All Atom open-source releases, model-only positioning without proprietary training-corpus, wet-lab-throughput, generative-hypothesis-testing loop gets commoditized within 6-12 months, and pharma-BD, venture underwriters demand a defensible-data-flywheel (Basecamp BaseGraph 9.8B, Recursion Phenom 25+ petabyte, Terray $1T+ measurements, Absci 6M+ antibody-binding/week, Xaira Baker, wet-lab, Ginkgo foundry, Adaptyv testing-loop) as gating for Series A+. Ignoring FDA CDER, CBER, CDRH, Good Machine Learning Practice, 21 CFR Part 11, Part 820 QSR, ISO 13485, ICH E6 GCP, AI/ML SaMD, EMA, MHRA, PMDA, NMPA regulatory posture — bespoke or unvalidated ML pipelines get flagged by pharma-partner regulatory, QA, biostatistics teams during BD, due-diligence, IND-package review, killing $100M-$3B deals within a review-cycle. Underestimating pharma-BD sales-cycle, milestone-royalty economics — pharma-strategic-partnerships take 12-24 months from first-meeting to signed-deal, require published-benchmark, independent-validation, wet-lab-repro, biostatistics, toxicology, ADMET, IND-package-track record, and typical deal-structure is $10-100M upfront, $200M-$3B milestones, 5-15% royalty spread across 5-15 year timeline — startups without a 24-36 month runway, program-slate depth, pharma-BD leadership burn out before closing meaningful deals. Ignoring the AI Bio-Risk, biosecurity, BSL-2/3/4, BIS export-controls on frontier-bio-AI Jan-2025, White House EO 14110, Bletchley, Seoul, Paris AI Safety Summit biosecurity commitments, AI Bio-Risk Report (RAND, Anthropic, OpenAI, DeepMind 2024) — dual-use, gain-of-function-adjacent, pathogen-design-adjacent generative-bio-AI programs face immediate regulatory, investor, partner-university biosafety-committee blocking, and post-2024-2026 biosecurity-tightening any pitch without a public biosecurity, red-teaming, pathogen-guardrails, KYC-on-DNA-synthesis-orders posture gets binned. Underestimating compute, Nvidia, BioNeMo, Preferred Partner tier, AWS, Google Cloud, Azure, CoreWeave, Nebius, Lambda, Together AI, Crusoe cost — training, inference for a frontier bio-foundation-model requires $20-100M+ compute-spend across H100, H200, B200, GB200, Blackwell Ultra, BioNeMo, Clara Discovery stack, and non-Nvidia-Preferred-Partner operators wait 6-12+ months for latest-silicon allocation. Ignoring the pharma, tech, hyperscaler strategic-anchor pattern — most $500M-$3B outcomes will be pharma-strategic-acquisition, partnership, milestone-royalty (Novartis, Lilly, Roche, BMS, Merck, AstraZeneca, GSK, Amgen, Sanofi, Pfizer, Takeda, Boehringer, Bayer, Novo Nordisk, Regeneron, Vertex) or hyperscaler, Nvidia strategic-anchor (Isomorphic-Alphabet, Evolutionary Scale-Amazon-Nvidia, Ginkgo-Google $1.1B Aug-2024, Recursion-Nvidia $250M Jul-2023), not $10B+ IPOs.

Frequently asked questions

Is there room for another AI-biology foundation-model or generative-protein startup vs. AlphaFold 3, ESM3, Chai-2, Boltz-2, RFdiffusion All Atom, Isomorphic, Xaira?
Yes, at the vertical-therapeutic-area, closed-loop-wet-lab, proprietary-data, generative-chemistry, antibody-specific, digital-cell, omics, oncology, CNS, fibrosis, longevity, agriculture, biomanufacturing layers where foundation-model-only incumbents don't own wet-lab, hypothesis-testing-loop, clinical-progression. Defensible wedges are (a) biology foundation model, platform (Evolutionary Scale ESM3, Chai Discovery Chai-1, Chai-2, Isomorphic AlphaFold 3, Basecamp BaseGraph, BaseFold, Boltz-1, Boltz-2, Latent Labs, 310.ai), (b) generative-protein, antibody design (Xaira, Generate:Biomedicines Chroma, Absci, Nabla Bio, Cradle Bio, Genesis GEMS, Cyrus, Menten, Meloria, Adaptyv, Manas AI), (c) generative-small-molecule, chemistry (Iambic Enchant, Neural PLEX, Enveda PRISM, Terray tera-scale, Insilico Pharma.AI, Recursion LOWE, Exscientia, Genesis GEMS, PostEra, Cadence Molecular, Schrödinger $SDGX, Nimbus), (d) digital-cell, omics, spatial (Recursion Phenom, Terray, Ginkgo-Google $1.1B, Genesis, Enveda, Basecamp, Insitro-DiSH, iPSC, Immunai, Charm, Etcembly, Neumora-Amgen, Owkin, Deep Genomics), (e) closed-loop wet-lab, robotics (Emerald Cloud Lab-Strateos-Culture-Arctoris-Ganymede-Benchling-LatchBio-Colossal, Adaptyv, Absci-Merck-AstraZeneca, Recursion-Bayer, Xaira-Sanofi, Terray, Iambic, Genesis-Amgen, Insilico-Sanofi, Isomorphic-Novartis-Lilly), (f) vertical-application — antibody-discovery, oncology, autoimmune (Xaira, Absci, Nabla, Generate, Cradle), CNS, neurodegeneration (Neumora-Amgen, Insitro), fibrosis, aging, longevity (Insilico, Retro, Altos), agriculture, biomanufacturing (Ginkgo, Basecamp, Cradle enzyme-engineering).
How exposed is an AI-biology startup to DeepMind Isomorphic, Meta FAIR ESM, OpenAI, Anthropic, Nvidia BioNeMo hyperscaler first-party research?
Very meaningfully — DeepMind Isomorphic (AlphaFold 3 May-2024 Nature, $1.7B Novartis-Lilly deals, $600M Apr-2025 first external round), Meta FAIR ESM Metagenomic Atlas 9B+ proteins, ESM3 open, OpenAI Life Sciences (Retro Biosciences $180M partnership 2023, Chai Discovery investor Sep-2024), Anthropic Claude Bio-adj, AI Bio-Risk Report Sep-2024, Nvidia BioNeMo, Clara Discovery, DGX Cloud, Preferred Partner tier all have first-party compute, model, data, partnership advantages. Defensible wedges are (a) proprietary wet-lab, closed-loop, data-generating advantage that hyperscalers don't have (Basecamp BaseGraph 9.8B, Recursion Phenom 25+ petabyte, Terray $1T+ measurements, Absci 6M+ antibody-binding/week, Xaira Baker, wet-lab, Ginkgo foundry, Adaptyv testing-loop), (b) pharma-BD, strategic-partnership, milestone-royalty economics (Isomorphic-Novartis-Lilly $1.7B, Genesis-Lilly, Recursion-Bayer-Roche-Sanofi, Xaira-Sanofi, Absci-AstraZeneca-Almirall-Merck, Insilico-Sanofi, Terray-BMS, Ginkgo-Google $1.1B, Novo Nordisk, Cradle-Novartis-Bayer, Iambic-BMS, Enveda-BMS, PostEra-Moderna), (c) clinical-asset progression, IND-enabling, Phase 1/2 readouts (Insilico INS018_055 Phase 2, Recursion REC-994, REC-2282, REC-4881 in Phase 2/3), (d) vertical-therapeutic-area depth (antibody, oncology, CNS, fibrosis, longevity, agriculture, biomanufacturing), (e) regulatory, biosecurity, BSL, BIS export-control posture (FDA GMLP, 21 CFR Part 11, Part 820 QSR, ISO 13485, ICH E6 GCP, White House EO 14110, NIST AI RMF, EU AI Act biotech, AI Bio-Risk Report, BIS export-controls on frontier-bio-AI Jan-2025), (f) Nvidia BioNeMo, Preferred Partner, AWS, Google Cloud, Azure, CoreWeave, Nebius, Lambda, Together AI, Crusoe compute, integration position where hyperscaler-native operators face conflict-of-interest, IP, data-sharing friction with pharma partners.
Realistic exit?
Pharma-strategic-acquisition, partnership, milestone-royalty, hyperscaler-strategic-anchor dominate; IPO is reserved for two or three category leaders. Recent comps: Recursion-Exscientia $712M all-stock merger Nov-2024 (combined $RXRX $3B+ market-cap), Xaira Therapeutics $1B seed Apr-2024 ARCH-Foresite-F-Prime-NEA-Sequoia-Lightspeed (largest bio-seed ever), Isomorphic Labs $600M Apr-2025 Thrive-GV-Alphabet, $1.7B Novartis-Lilly deals Jan-2024, Generate:Biomedicines $273M C Sep-2023 Nvidia-Amgen-Abu Dhabi $2.4B valuation, Insilico $95M E Mar-2024 Value Partners-Prosperity7 $1B+ valuation, Iambic $100M A Aug-2024 Nvidia-Ascenta-Catalio, Genesis $200M B Aug-2023 a16z-Nvidia-Menlo, Terray $120M B May-2024 Bracket-Two Bear-Nvidia, Enveda $55M C Oct-2024 Kinnevik-Nvidia, Cradle $73M B Jun-2024 IVP-Index-Kindred, Basecamp Research $60M B Sep-2024 Singular-S32-Coefficient, Latent Labs $50M seed Feb-2025 Radical-Sofinnova-GV, Chai Discovery $30M seed Sep-2024 Thrive-OpenAI-Dimension, Manas AI $24.6M Jan-2025 General Catalyst-Greylock, Nabla Bio $26M A Feb-2024 Radical-Menlo, Evolutionary Scale $142M seed Jun-2024 Nat Friedman-Daniel Gross-Amazon-Nvidia-Lux, plus Absci $ABS IPO Jul-2021, Recursion $RXRX IPO Apr-2021, Ginkgo $DNA SPAC Sep-2021, Schrödinger $SDGX IPO Feb-2020, plus pharma M&A — Lilly-Loxo $8B, BMS-Turning Point $4.1B, BMS-Karuna $14B, Merck-Prometheus $10.8B, Amgen-Horizon $28B, Pfizer-Seagen $43B, Sanofi-Owkin $700M partnership, Vertex-Alpine $4.9B, Novartis-MorphoSys $2.9B, Roche-Poseida $1.5B, Boehringer-T3-adj, Novo-Cardior $1B, AstraZeneca-Fusion $2.4B. Likely strategic acquirers, partners: Novartis $NVS, Eli Lilly $LLY, Roche, Genentech $RHHBY, Bristol Myers Squibb $BMY, Merck $MRK, AstraZeneca $AZN, GSK $GSK, Amgen $AMGN, Sanofi $SNY, Pfizer $PFE, Takeda, Boehringer Ingelheim, Bayer, Novo Nordisk $NVO, Regeneron $REGN, Vertex $VRTX, Biogen $BIIB, Moderna $MRNA, BioNTech $BNTX, plus hyperscaler, tech Google $GOOGL (Isomorphic, DeepMind, Ginkgo $1.1B), Microsoft $MSFT (BioNeMo-adj, AI4Science), Amazon $AMZN (Evolutionary Scale, AWS HealthLake), Nvidia $NVDA (BioNeMo, Clara, all portfolio, NVentures). IPO reserved for two or three category leaders at $100M+ revenue, clinical-stage pipeline — Recursion (public), Absci (public), Ginkgo (public), Schrödinger (public), Isomorphic, Xaira, Generate, Insilico, Cradle, Iambic, Terray, Enveda on 3-5 year IPO horizon; most likely near-term path is pharma, hyperscaler strategic-partnership, milestone-royalty, M&A.

Related fundraising verticals (40)

Investor directory · Fundraising library · Articles A–Z · Company funding database